Documented failures in LLM systems, from wrongful death claims to AI Overviews siphoning clicks, show why SEOs must audit, attribute, and defend brand visibility.
Novartis has reported successful Phase III results for GanLum, a new non-artemisinin antimalarial designed to combat growing ...
Basel: Novartis has announced positive results from KALUMA, a Phase III study for new malaria treatment KLU156 ...
Good Good Good on MSN
12 Famous Veterinarians Who Inspire Us To Do Good
Veterinary science has become an innovative field, taking care of our beloved pets, but also to making breakthroughs that ...
Novartis phase III trial for next-generation malaria treatment KLU156 meets primary endpoint, with potential to combat antimalarial resistance: Basel Friday, November 14, 2025, 09 ...
Novartis' GanLum met key Phase 3 goals, showing strong efficacy and safety in malaria patients, including against resistant ...
Clinical Trials Arena on MSN
Novartis to seek approval of anti-malaria drug on Phase III success
Based on the Phase III data, Novartis plans to seek regulatory approval from health authorities for GanLum, with the company adding that it could mark the first major innovation in malaria treatment ...
An experimental drug was effective against malaria in a new study, potentially offering a much-needed buffer against the ...
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
The treatment — which could be the first novel antimalarial in decades — showed the ability in testing to combat drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback